These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8674002)

  • 61. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases.
    Molina R; Jo J; Filella X; Bruix J; Castells A; Hague M; Ballesta AM
    Tumour Biol; 1997; 18(3):188-96. PubMed ID: 9143415
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Serum levels of c-erbB-2 protein in patients with breast cancer: preliminary report].
    Ohuchi N; Abe M; Harada Y; Furuta A; Ikegaki H; Mori S
    Nihon Geka Gakkai Zasshi; 1991 Oct; 92(10):1530. PubMed ID: 1961194
    [No Abstract]   [Full Text] [Related]  

  • 63. Antipapain activity in the serum of patients with breast cancer.
    Kilar E; Gworys B; Skiba T; Gburek J; Gołąb K; Janocha A; Siewiński M
    Cancer Biomark; 2015; 15(1):99-102. PubMed ID: 25524947
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinicopathological significance of erbB-2 expression in colorectal carcinoma.
    Chamberlain NL; Ward RL; Hawkins NJ
    Oncol Rep; 1999; 6(3):527-31. PubMed ID: 10203586
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.
    Hayes DF; Walker TM; Singh B; Vitetta ES; Uhr JW; Gross S; Rao C; Doyle GV; Terstappen LW
    Int J Oncol; 2002 Nov; 21(5):1111-7. PubMed ID: 12370762
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Serum levels of c-erbB-2 protein in digestive diseases.
    Motoo Y; Sawabu N; Yamaguchi Y; Mouri I; Yamakawa O; Watanabe H; Ohta H; Okai T; Makino H
    J Gastroenterol; 1994 Oct; 29(5):616-20. PubMed ID: 7528080
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies.
    Brandt-Rauf PW
    Mutat Res; 1995 Dec; 333(1-2):203-8. PubMed ID: 8538628
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.
    Molina R; Augé JM; Escudero JM; Filella X; Zanon G; Pahisa J; Farrus B; Muñoz M; Velasco M
    Tumour Biol; 2010 Jun; 31(3):171-80. PubMed ID: 20361287
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors.
    Papila C; Uzun H; Balci H; Zerdali H; Sezgin C; Can G; Yanardag H
    Med Oncol; 2009; 26(2):151-6. PubMed ID: 18855148
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
    Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
    Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
    Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
    Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
    Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
    Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
    Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
    J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Serial serum c-erbB-2 levels in patients with breast carcinoma.
    Volas GH; Leitzel K; Teramoto Y; Grossberg H; Demers L; Lipton A
    Cancer; 1996 Jul; 78(2):267-72. PubMed ID: 8674002
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.